Why Biodesix, Inc.’s (BDSX) Stock Is Down 9.03%
As of Monday, November 16, Biodesix, Inc.’s BDSX share price has dipped by 9.03%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Tudor Pop
Jenna Brashear
| Share Statistics | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $98.5 | $1,953.4 | 23% |
|
| Shares Out (Mil) | 10.7 | 80.6 | 22% |
|
| Institutional Ownership | 42.7% | 87.3% | 18% |
|
| Float (Mil) | 5.4 | 58.7 | 13% |
|
| Beta | 0.63 | 0.75 | 36% |
|
| Avg Daily Volume (000s) | 505 | 658 | 57% |
|
| Price Change (52-week) |
11.0% | 81.4% | 62% |
|
| Growth | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.2% | 10.4% | 71% |
|
| Net Income (5yr) | (2.4%) | (0.5%) | 37% |
|
| EPS (5yr) | 48.6% | 3.0% | 92 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (17.4%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $105 | $1,529 | 26% |
|
| Net Income (TTM) (Mil) | ($27) | $33 | 21% |
|
| EPS (TTM) | ($2.799) | $0.300 | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | $175 | 16% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $7 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $70 | $419 | 41% |
|
| Enterprise Value (Q1) (Mil) | $144 | $2,427 | 25% |
|
| Valuation | BDSX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 11.38 | 2.83 | 93% |
|
| P/E | na | 27.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | BDSX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 82.4% | 27.3% | 90% |
|
| Net Margin | (25.7%) | 1.4% | 15% |
|
| ROA | (29.6%) | 2.4% | 16% |
|
| ROE | (778.9%) | 7.3% | 0% |
|
| Liabilities to Assets | 90.8% | 61.5% | 87% |
|
| F-Score | 5 | 5 | 50% |
|
Biodesix, Inc. did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors